Research Topics
Genomes and Genes
| S G PotkinSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A Thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidoneSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine Irvine, CA 92697 3960, USA
J Clin Psychopharmacol 33:3-10. 2013..The only cardiovascular adverse events with iloperidone were non-concentration-dependent tachycardia that was mild in most patients and did not lead to further sequelae. Pharmacogenetics and recommendations are discussed...
Nicotine-induced brain metabolism associated with anger provocationJEAN G GEHRICKE
Department of Psychiatry and Human Behavior, University of California, Irvine, 19722 MacArthur Blvd, Irvine, California 92612, USA
Behav Brain Funct 5:19. 2009..These findings reveal the underlying brain circuitry targeted by nicotine during anger provocation...- SNP-based pathway enrichment analysis for genome-wide association studiesLingjie Weng
Department of Computer Science, University of California, Irvine, USA
BMC Bioinformatics 12:99. 2011..Most current methods choose the most significant SNP from each gene as a representative, ignoring the joint action of multiple SNPs within a gene. This approach leads to preferential identification of genes with a greater number of SNPs... - Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studiesSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92697 3960, USA
J Clin Psychopharmacol 28:S4-11. 2008..These trials indicate that iloperidone is effective for the treatment of schizophrenia... 
New advances in the treatment of schizophrenia. IntroductionSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine and UCI Medical Center Brain Imaging Center, Orange, CA 92868-3298, USA
J Clin Psychopharmacol 28:S1-3. 2008- Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trialSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, Brain Imaging Center, CA 92697 3960, USA
J Clin Psychiatry 68:1492-500. 2007..This 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (DSM-IV criteria)... - A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalizationSteven G Potkin
University of California, Irvine, Orange, 92696, USA
Schizophr Res 85:254-65. 2006..This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization... - Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerationsSteven G Potkin
Department of Psychiatry and Human Behavior, University California of Irvine, Irvine, CA, USA
Cogn Neuropsychiatry 14:391-418. 2009..GWASs make it possible to survey the entire genome to discover important but unanticipated genetic influences... - Psychometric evaluation of the Readiness for Discharge QuestionnaireSteven G Potkin
University of California, Irvine, Department of Psychiatry and Human Behavior, Brain Imaging Center, Irvine Hall, Room 166, Orange, CA, USA
Schizophr Res 80:203-12. 2005..The psychometric properties of the RDQ are described... - Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trialSteven G Potkin
Neuropsychiatric Center, University of California Irvine, 101 City Drive South, Bldg 3, Orange, CA 92868 3298, USA
J Clin Psychopharmacol 25:301-10. 2005..In an earlier 21-day, placebo-controlled trial, ziprasidone was efficacious in improving symptoms of mania and was well tolerated. To confirm these results, a similarly designed 21-day trial was conducted... - Asenapine: a clinical overviewSteven G Potkin
Department of Psychiatry, UCI Brain Imaging Center, University of California Irvine, 5251 California Avenue, Irvine, CA, USA
J Clin Psychiatry 72:14-8. 2011..Asenapine may be a helpful treatment option for patients with schizophrenia when weight gain, dyslipidemia, and endocrine abnormalities are a concern... - Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortiumSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92617, USA
Schizophr Bull 35:15-8. 2009..identified six genes that influence DLPFC activation and have functions related to forebrain development and stress responses in schizophrenia. These related publications indicate the power of multisite neuroimaging... - A genome-wide association study of schizophrenia using brain activation as a quantitative phenotypeSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92617, USA
Schizophr Bull 35:96-108. 2009..We present an alternative strategy with increased statistical power over a case-control study that uses brain imaging as a quantitative trait (QT) in the context of a GWAS in schizophrenia... - Working memory and DLPFC inefficiency in schizophrenia: the FBIRN studyS G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA 92617, USA
Schizophr Bull 35:19-31. 2009..Both prefrontal hyper- or hypoactivity in chronic schizophrenia have been found in previous studies of working memory... - Gene discovery through imaging genetics: identification of two novel genes associated with schizophreniaS G Potkin
Department of Psychiatry and Human Behavior, Brain Imaging Center, University of California, Irvine, CA 92617, USA
Mol Psychiatry 14:416-28. 2009..We introduce the use of functional magnetic resonance imaging activation as a quantitative phenotype in conjunction with genome-wide association as a gene discovery tool... - Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidolSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA
Int J Neuropsychopharmacol 12:1233-48. 2009..In this long-term, double-blind study, ziprasidone treatment was more likely to result in remission than haloperidol treatment, and was associated with greater improvement in quality-of-life... - Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's diseaseSteven G Potkin
Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA, USA
PLoS ONE 4:e6501. 2009..With the exception of APOE epsilon4 allele, the common genetic risk factors for sporadic Alzheimer's Disease (AD) are unknown... - Identifying gene regulatory networks in schizophreniaSteven G Potkin
Department of Psychiatry and Human Behavior, 5251 California Avenue, Suite 240, University of California, Irvine, CA 92617, USA
Neuroimage 53:839-47. 2010..The model demonstrates epistatic interactions between FGF and glypican on brain development and may be a useful model of negative symptom schizophrenia... - Placebo response trajectories in short-term and long-term antipsychotic trials in schizophreniaSteven Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA 92617, USA
Schizophr Res 132:108-13. 2011..Further research is warranted to examine the trajectory patterns of placebo responses in independent patient populations... - Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorderSteven G Potkin
Department of Psychiatry, Human Behavior, University of California at Irvine, Irvine, CA 92617, United States
Schizophr Res 132:101-7. 2011..The current study evaluated the safety and efficacy of lurasidone and ziprasidone in stable outpatients diagnosed with schizophrenia or schizoaffective disorder... - Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorderSteven G Potkin
Brain Imaging Center, University of California, Irvine, 92697, USA
Arch Gen Psychiatry 60:681-90. 2003..This multicenter trial examined the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schizophrenia or schizoaffective disorder... - The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patientsSteven G Potkin
Department of Psychiatry and Human Behavior, University of California at Irvine Medical Center, Orange, California 92668, USA
Int Psychogeriatr 14:7-26. 2002..Rivastigmine robustly inhibits butyrylcholinesterase in addition to AChE and therefore acts as a dual ChE inhibitor. Comparative studies evaluating the differential effects of these ChE inhibitors on ADL are awaited... - Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerabilitySteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine Medical Center, Orange, California, USA
Clin Ther 24:1809-23. 2002..The aim of this study was to assess the effect of oral quetiapine on the steady-state pharmacokinetics of lithium... - Brain metabolic and clinical effects of rivastigmine in Alzheimer's diseaseS G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92627 3960, USA
Int J Neuropsychopharmacol 4:223-30. 2001..Rivastigmine prevented the expected deterioration in clinical status and dramatically increased brain metabolic activity in a majority of patients... - Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicideSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Room 166, Irvine Hall, Irvine, CA 92697 3960, USA
Schizophr Res 59:59-66. 2003.... - A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomographySteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine 92697 3960, USA
Am J Psychiatry 159:227-37. 2002.... - The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazineSteven G Potkin
UC Irvine Medical Center, Department of Psychiatry and Human Behavior, Orange, California, USA
J Clin Psychopharmacol 22:121-30. 2002..Thioridazine significantly increased the oral clearance of quetiapine. Increased doses of quetiapine may be necessary to control psychotic symptoms when thioridazine is coadministered with quetiapine... - Brain metabolic effects of Neotrofin in patients with Alzheimer's diseaseSteven G Potkin
Department of Psychiatry and Human Behavior, Brain Imaging Center, Irvine Hall, Room 166, University of California, Irvine, Irvine, CA 92697 3960, USA
Brain Res 951:87-95. 2002..Thus, Neotrofin appears to induce metabolic changes in brain regions involved in circuits underlying memory, attention, and executive functioning... - D1 receptor alleles predict PET metabolic correlates of clinical response to clozapineS G Potkin
Department of Psychiatry and Human Behavior, University of Caliornia, Irvine 92697 3960, USA
Mol Psychiatry 8:109-13. 2003..05). In this preliminary study, brain metabolic and clinical response to clozapine are related to the D1 receptor genotype... - Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapineSteven G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, Medical Center, Orange, USA
J Clin Psychopharmacol 22:174-82. 2002..No unexpected side effects were reported. In conclusion, combination therapy with quetiapine and fluoxetine or imipramine had a minimal effect on quetiapine pharmacokinetics and was well tolerated... - Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe diseaseSteven G Potki
Brain Imaging Center, Department of Psychiatry and Human Behavior, University of California, Irvine 92697, USA
Prog Neuropsychopharmacol Biol Psychiatry 26:713-20. 2002..To investigate the relationship between activities of daily living (ADL) impairment and Alzheimer's disease (AD) severity in mild to moderately severe AD patients receiving the cholinesterase (ChE) inhibitor rivastigmine... - Clozapine enhances neurocognition and clinical symptomatology more than standard neurolepticsS G Potkin
Department of Psychiatry and Human Behavior, University of California, Irvine, UCI Medical Center, Orange 92686, USA
J Clin Psychopharmacol 21:479-83. 2001..The superiority of clozapine over haloperidol may be related to clozapine's unique psychopharmacologic profile... - Structured Interview for Assessing Perceptual Anomalies (SIAPA)W E Bunney
Department of Psychiatry and Human Behavior, University of California, Irvine 92717, USA
Schizophr Bull 25:577-92. 1999..The data indicate that the putative phenomenological correlates of sensory gating may be reliably measured and tested with the Structured Interview for Assessing Perceptual Anomalies... - Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenicsS Akbarian
Department of Anatomy and Neurobiology, University of California, Irvine 92717, USA
J Neurosci 16:19-30. 1996..In schizophrenics, the alterations in expression of NR2 subunit mRNA in prefrontal cortex are potential indicators of deficits in NMDA receptor-mediated neurotransmission accompanying functional hypoactivity of the frontal lobes... - A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trialStephen M Stahl
Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
J Clin Psychopharmacol 30:425-30. 2010.... - Gender: a major determinant of brain response to nicotineJames H Fallon
Department of Anatomy and Neurobiology, BIRN-RP, University of California, Irvine, CA 92697-3960, USA
Int J Neuropsychopharmacol 8:17-26. 2005..The overall effect of nicotine was to decrease these gender differences in brain metabolism... - Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjectsE C Mormino
Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, USA
Brain 132:1310-23. 2009..This pattern suggests that declining EM in older individuals may be caused by Abeta-induced hippocampus atrophy... - fMRI activity correlated with auditory hallucinations during performance of a working memory task: data from the FBIRN consortium studyC G Wible
Department of Psychiatry, Harvard Medical School and Brockton VAMC, Boston, MA 02115, USA
Schizophr Bull 35:47-57. 2009..We hypothesized that regions involved in verbal working memory and language processing would show activity that was associated with levels of hallucinations during a condition where subjects were rehearsing the stimuli... - Effects of clozapine and thiothixene on glucose metabolic rate in schizophreniaM S Buchsbaum
Department of Psychiatry, University of California, Irvine 92717
Neuropsychopharmacology 6:155-63. 1992..Larger sample studies are needed to replicate and extend these initial findings... - Imaging phenotypes and genotypes in schizophreniaJessica A Turner
Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92697, USA
Neuroinformatics 4:21-49. 2006.... - Synthesis and evaluation of nicotine alpha4beta2 receptor radioligand, 5-(3'-18F-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine, in rodents and PET in nonhuman primateSankha Chattopadhyay
Department of Psychiatry and Human Behavior. Brain Imaging Center, University of California, Irvine, CA 92697, USA
J Nucl Med 46:130-40. 2005..Additionally, the thalamus-to-cerebellum ratio approached a plateau of 1.7 in 120 min, indicating relatively faster kinetics compared with previously reported imaging agents... - Three-month change in cerebral glucose metabolism in patients with nonarteritic ischemic optic neuropathyS Bose
Department of Ophthalmology, University of California, Irvine, 118 Med Surge I, Irvine, CA 92697, USA
Graefes Arch Clin Exp Ophthalmol 244:1052-5. 2006..Positron emission tomography (PET) to determine the change in glucose metabolic rate in the visual cortex of patients with NAION versus age-matched controls was performed after 3 months' administration of pentoxifylline... - Sex-related difference in amygdala activity during emotionally influenced memory storageL Cahill
Department of Neurobiology and Behavior, Center for the Neurobiology of Learning and Memory, CA 92697 3800, USA
Neurobiol Learn Mem 75:1-9. 2001.... - Smoking to self-medicate attentional and emotional dysfunctionsJEAN G GEHRICKE
Department of Psychiatry and Human Behavior, D402 Medical Sciences I, Irvine, California 92697 1674, USA
Nicotine Tob Res 9:S523-36. 2007.... - Multivariate analyses suggest genetic impacts on neurocircuitry in schizophreniaEmanuela Tura
Departments of Psychiatry and Human Behavior, University of California, Irvine, California 92617, USA
Neuroreport 19:603-7. 2008..Two groups of schizophrenic patients with similar symptomatology and performance on a working memory task, but with distinct dopamine receptor genotypes, may use distinct neural systems to retrieve information... - What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?Aaron S Kemp
UCI Neuropsychiatric Center, 101 The City Drive South, Orange, CA 92868, USA
Schizophr Bull 36:504-9. 2010..The session closed with a roundtable discussion and recommendations for data sharing to further explore potential causes and viable solutions to be applied in future trials... - Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohortAnita Lakatos
Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92617, USA
Neurobiol Aging 31:1355-63. 2010..Our results indicate that the mitochondrial haplogroup UK may confer genetic susceptibility to AD independently of the apolipoprotein E4 (APOE4) allele... - Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorderJoseph C Wu
Department of Psychiatry and Human Behavior, University of California at Irvine School of Medicine, Room 109, Irvine Hall, Irvine, CA 92697 3960, USA
Biol Psychiatry 66:298-301. 2009..This study evaluates the combined efficacy of three established circadian-related treatments (SD, bright light [BL]), sleep phase advance [SPA]) as adjunctive treatment to lithium and antidepressants... - Working memory circuitry in schizophrenia shows widespread cortical inefficiency and compensationMiyoung A Kim
Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92617, USA
Schizophr Res 117:42-51. 2010..g. neural inefficiencies). We employed a data-driven, multivariate analysis to identify the patterns of brain-behavior relationships in SZ during working memory... - Brain-performance correlates of working memory retrieval in schizophrenia: a cognitive modeling approachGregory G Brown
Department of Psychiatry, University of California, San Diego, CA, USA
Schizophr Bull 35:32-46. 2009..The results show at both cognitive and neural levels that disordered memory scanning contributes to deficient SIRP performance among schizophrenia patients... - Alpha EEG predicts visual reaction timeYi Jin
Department of Psychiatry and Human Behavior, University of California Irvine College of Medicine, Irvine, California 2868 3298, USA
Int J Neurosci 116:1035-44. 2006..These findings are consistent with previous reports and support the hypothesis that alpha EEG represents excitability cycles and may serves as a brain clock for spatial synchronization... - Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trialSteven G Potkin
Brain Imaging Center, University of California, Irvine, California 92697-3960, USA
Biol Psychiatry 54:444-52. 2003..Assessment of these risk factors may aid clinicians in evaluating risk for suicidal behaviors so that appropriate interventions can be made... - Hostility differentiates the brain metabolic effects of nicotineJames H Fallon
Department of Anatomy and Neurobiology, University of California, Irvine, BIRN-RP, 5251 California, Suite 240, Irvine, CA 92697-3960, USA
Brain Res Cogn Brain Res 18:142-8. 2004..This biological difference in brain metabolic response to nicotine between high and low hostility trait subjects may explain differences in susceptibility to nicotine dependence... - Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (alphaTMS) on the negative symptoms of schizophreniaYi Jin
Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine, USA
Schizophr Bull 32:556-61. 2006..These results affirm that the resonant features of alpha frequency EEG play an important role in the pathophysiology of schizophrenia and merit further investigation as a particularly efficacious frequency for rTMS treatments... - Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primateNeil Saigal
Brain Imaging Center, Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, California 92697 3960, USA
J Nucl Med 47:1697-706. 2006..We have synthesized N-{2-[4-(2-methoxyphenyl)piperazinyl]ethyl}-N-(2-pyridyl)-N-(4-18F-fluoromethylcyclohexane)carboxamide (18F-mefway), which contains a 18F on a primary carbon to make the compound more stable to defluorination... - Alzheimer disease and other dementiasGustavo Alva
Department of Psychiatry and Human Behavior, University of California, Irvine, 101 The City Drive, Orange, CA 92868, USA
Clin Geriatr Med 19:763-76. 2003..Palliative ways of slowing progressive decline are available primarily by way of ChEIs, although no cures yet exist for the dementias. Optimizing current treatments makes sense in improving the quality of life of sufferers... - EEG resonant responses in schizophrenia: a photic driving study with improved harmonic resolutionY Jin
From the Department of Psychiatry and Human Behavior, University of California, Irvine Medical Center, Orange CA 92868, USA
Schizophr Res 44:213-20. 2000.... - Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatientsG M Asnis
Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 111 E 210th Street, Bronx, New York, NY 10467 2490, USA
Psychiatry Res 103:1-14. 2001..Significant improvement was evident as early as week 1 for some panic variables. Fluvoxamine is a potent anti-panic agent with a relatively rapid onset of action... - Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competitionBalasubramaniam Easwaramoorthy
Brain Imaging Center, Department of Psychiatry and Human Behavior, University of California, Irvine, California 92697, USA
Synapse 61:29-36. 2007..The effect is AChEI-concentration dependent and is greater for PHY than GAL. Thus (18)F-nifene has promise for assessing ACh levels and AChEI effects in vivo... - Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primateRama Pichika
Brain Imaging Center, Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92697-3960, USA
Nucl Med Biol 33:295-304. 2006..Thalamus-to-cerebellum ratio peaked at 30-35 min postinjection to a value of 2.2 and subsequently reduced. The faster binding profile of 18F-nifene indicates promise as a PET imaging agent and thus needs further evaluation... - GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controlsS Akbarian
Department of Anatomy and Neurobiology, University of California, Irvine 92717, USA
Cereb Cortex 5:550-60. 1995.... - A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementiaSteven G Potkin
University of California, Irvine, California, USA
Drugs Aging 23:241-9. 2006..CONCLUSION: This pilot study suggests that rivastigmine treatment may have beneficial effects in the treatment of patients with mixed dementia... - Circadian abnormalities, molecular clock genes and chronobiological treatments in depressionJennifer N Bunney
University of Southern California, Los Angeles, CA, USA
Br Med Bull 86:23-32. 2008..It is hypothesized that fast-acting treatments for depression may alter circadian rhythms through chronobiological mechanisms relevant to clock gene function... - Memory for emotional stimuli in patients with Alzheimer's diseaseKirsten Fleming
Department of Psychiatry and Human Behavior, University of California, Irvine, California, USA
Am J Alzheimers Dis Other Demen 18:340-2. 2003..These findings of improved immediate memory for emotional material in AD lends support to the notion that mnemonic functions are differentially affected in the disease... - Language in dreaming and regional EEG alpha powerC C Hong
Department of Psychiatry and Behavioral Medicine, University of California, Irvine, USA
Sleep 19:232-5. 1996..Our finding suggests lateralized and localized cortical activation in relation to language in dreaming... - MRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patientsMargherita Molnar
Center for Neuroscience, University of California, Davis, California 95616, USA
Biol Psychiatry 53:39-47. 2003..CONCLUSIONS: The findings that TBR1 and CAMKII-alpha expression is increased only in bipolar patients suggests abnormalities of specific genes related to a major cortical cell type and its connectivity... - A general XML schema and SPM toolbox for storage of neuro-imaging results and anatomical labelsDavid Bryant Keator
University of California, Irvine, CA
Neuroinformatics 4:199-212. 2006..htm). Support for anatomical labeling is available via the Talairach Daemon (http://ric.uthscsa. edu/projects/talairachdaemon.html) and Automated Anatomical Labeling (http://www. cyceron.fr/freeware/)... - Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophreniaPhilip D Harvey
Mt Sinai School of Medicine, New York University, 1425 Madison Avenue, Fourth Floor, New York, NY 10029, USA
Schizophr Res 66:101-13. 2004.... - A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer diseaseMark H Tuszynski
Department of Neurosciences, University of California at San Diego, La Jolla 92093, USA
Nat Med 11:551-5. 2005..05) increases in cortical 18-fluorodeoxyglucose after treatment. Brain autopsy from one subject suggested robust growth responses to NGF. Additional clinical trials of NGF for Alzheimer disease are warranted... - Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitorsSerge Gauthier
McGill Centre for Studies in Aging, Verdun, Quebec, Canada
Curr Med Res Opin 19:707-14. 2003..The panel also aimed to reach consensus on 'whom to switch', 'when to switch' and 'how to switch'. The key findings from that meeting are reported in this review... - Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesiaTakahiro Shinkai
Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Ont, Canada M5T 1R8
Neurosci Lett 388:116-20. 2005..1, p=1.00) were observed between subjects with and without TD. Our results suggest that the GSTP1 gene polymorphism does not confer increased susceptibility to TD, although further studies are warranted before a conclusion can be drawn... - Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment responseRudi Hwang
Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
J Psychopharmacol 21:718-27. 2007..2003), a trend in the same direction was observed as well. Our findings suggest that the rs4532 SNP may have a small effect if any. Further studies in larger, independent samples are required to validate these findings... - Chronic smoking and the BOLD response to a visual activation task and a breath hold task in patients with schizophrenia and healthy controlsLee Friedman
PO Box 51, Newbury, OH 44065, USA
Neuroimage 40:1181-94. 2008.... - Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophreniaKatherine A Albert
Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, USA
Arch Gen Psychiatry 59:705-12. 2002..CONCLUSIONS: Our findings are consistent with a selective reduction in DARPP-32 levels in schizophrenic subjects. This may be involved in the prefrontal dysfunction associated with schizophrenia... - Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patientsClement C Zai
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Int J Neuropsychopharmacol 10:639-51. 2007..047). Taken together, the present study suggests that DRD2 may be involved in TD in the Caucasian population, although further studies are warranted... - Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trialElaine R Peskind
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine and Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Seattle, WA 98108, USA
Am J Geriatr Psychiatry 14:704-15. 2006..The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD)... - Pharmacogenomics in schizophrenia: the quest for individualized therapyVincenzo S Basile
Neurogenetics Section, Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Toronto, Canada
Hum Mol Genet 11:2517-30. 2002..To the extent that the above data become more widely verified and replicated, the field of psychiatry will move closer to clinically meaningful tests that will be useful in deciding the best drug for each individual patient... - Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophreniaPeter J Weiden
Department of Psychiatry, SUNY Downstate Medical Center State, Brooklyn, NY 11203, USA
J Clin Psychiatry 64:580-8. 2003.... - Targeting acetylcholinesterase and butyrylcholinesterase in dementiaRoger M Lane
Novartis Neuroscience, Novartis Pharmaceuticals Corporation, NJ, USA
Int J Neuropsychopharmacol 9:101-24. 2006.... - Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation studyAntony D Loebel
Pfizer Inc, New York, NY 10018, USA
J Clin Psychiatry 68:1333-8. 2007..To evaluate the efficacy, safety, and tolerability of long-term ziprasidone therapy in treatment-resistant schizophrenia...
Research Grants
- Function BIRNSteven Potkin; Fiscal Year: 2007..When completed, researchers in different fields and physical locations will be able to draw on a common set of tools and database systems not possible at a single site. ..
- Transdisciplinary Imaging Genetics Center (1 of 2)(RMI)Steven Potkin; Fiscal Year: 2006..These goals could not be achieved without a unifying Center focused on a single integrative theme. The new knowledge generated by the Center holds considerable promise for improving diagnosis and treatment of mental illness. ..
- PET IMAGING & MAPPINGSteven Potkin; Fiscal Year: 2002..3. Retrospect ively evaluate the fMRI structural and neuropsychological data, comparing the performance of those who did and did not show cognitive declines beyond normal age-associated memory impairment (AAMI). ..